Highlights and Quick Summary
- Annual 3Y Total Assets Growth (CAGR) for 2021 was 70.1% (a -1108.63% decrease from previous year)
- Annual 3Y Total Assets Growth (CAGR) for 2020 was -6.95% (a -86.95% decrease from previous year)
- Annual 3Y Total Assets Growth (CAGR) for 2019 was -53.27% (a 29.26% increase from previous year)
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.
Historical 3Y Total Assets Growth (CAGR) of Neovasc Inc.Most recent 3Y Total Assets Growth (CAGR)of NVCN including historical data for past 10 years.
Interactive Chart of 3Y Total Assets Growth (CAGR) of Neovasc Inc.
Neovasc Inc. 3Y Total Assets Growth (CAGR) for the past 10 Years (both Annual and Quarterly)
Business Profile of Neovasc Inc.
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.